newsfilter
← Latest News
Business Wire·

Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Clinical stage programs focused on rare hematologic diseases and cancers Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III